Docquity delivers 10% market share growth for Philippine-based pharmaceutical client in just one year
Docquity's leading network of HCPs and proprietary Awareness to Advocacy (A2A) solution complemented the Client's Sales and Marketing team to increase conversions in a highly competitive pain product market Client was able to grow prescriptions and revenue, with over 80% cost savings compared to traditional approaches MANILA, Philippines, Jan. 18,...
Keymed Biosciences | The Latest Results from the Phase Ia Clinical Study of CMG901 was presented at the 2023 ASCO GI CANCERS SYMPOSIUM
CHENGDU, China, Jan. 18, 2023 /PRNewswire/ -- Keymed Biosciences Inc. (Stock Code: 02162 HK) is pleased to announce that the latest data from the Phase Ia dose-escalation trial of CMG901 (Claudin 18.2 antibody drug conjugate), a novel drug candidate, for advanced solid tumors will be presented as a poster at the 2023 Gastrointestinal Cancers Symposium of the American Society...
Mental health focus makes Boehringer Ingelheim stand out as Top Employer 2023 in Asia Pacific for Third Consecutive Year
Boehringer Ingelheim is one of 15 global Top Employers worldwide Achieved Global Recognition and Top Employer Certification in 29 countries From Top Employers Institute® Outstanding employer benefits with emphasis on wellbeing, attractive work environment, and rewards and recognition SINGAPORE, Jan. 18, 2023 /PRNewswire/ -- Boehringer Ingelheim has been awarded for the third year in succession a "Global Top...
Boehringer Ingelheim Malaysia Honored As Top Employer For The Fifth Consecutive Year
Boehringer Ingelheim is one of 15 global Top Employers worldwide Achieved Global Recognition and Top Employer Certification in 29 countries From Top Employers Institute® Outstanding employer benefits with emphasis on wellbeing, attractive work environment, and rewards and recognition KUALA LUMPUR, Malaysia, Jan. 18, 2023 /PRNewswire/ -- Boehringer Ingelheim has been awarded for the third year in succession...
Boehringer Ingelheim Indonesia Honored As Top Employer For The Fourth Consecutive Year
Boehringer Ingelheim is one of 15 global Top Employers worldwide Achieved Global Recognition and Top Employer Certification in 29 countries From Top Employers Institute® Outstanding employer benefits with emphasis on wellbeing, attractive work environment, and rewards and recognition JAKARTA, Indonesia, Jan. 18, 2023 /PRNewswire/ -- Boehringer Ingelheim has been awarded for the third year in succession a "Global...
Telix Reports Fourth Quarter 2022 Financial Results
MELBOURNE, Australia, Jan. 18, 2023 /PRNewswire/ -- 18 January 2023. Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today issues its Appendix 4C quarterly cash flow statement and accompanying Activities Report for the quarter ended 31 December 2022 (Q4 2022). All figures are in AUD$ unless otherwise stated1 and provided on an unaudited...
IASO Bio Raises Nearly $75 Million in Series C1 Funding
Approaches Commercialization of First Product NANJING and SHANGHAI, China and SAN JOSE, Calif., Jan. 18, 2023 /PRNewswire/ -- IASO Biotherapeutics (IASO Bio), a clinical-stage biopharmaceutical company engaged in discovering, developing, and manufacturing innovative cell therapies and antibody products, today announced the completion of nearly US $75 million ($500 million RMB) in Series...
Transcenta to Present “Trial in Progress” at ASCO-GI 2023 for TST001 (Osemitamab) Combination with Nivolumab, with or without Chemotherapy in Advanced G/GEJ Cancer
SUZHOU, China, Jan. 18, 2023 /PRNewswire/ -- Transcenta Holding Limited ("Transcenta") (HKEX: 06628), a clinical stage biopharmaceutical company with fully-integrated capabilities in discovery, research, development and manufacturing of antibody-based therapeutics, announces that it will present the design of 2 cohorts from a Phase I/IIa study of TST001, its high affinity humanized ADCC-enhanced anti-Claudin18.2 monoclonal antibody, in combination with Nivolumab...
Everest Medicines Announces Top-line Data from Phase I Study of EVER206 on Healthy Subjects in China
Study findings suggest that EVER206 is well-tolerated with no new safety signals, supporting next-phase clinical development in China SHANGHAI, Jan. 18, 2023 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest"), a biopharmaceutical company focused on the development, manufacturing and commercialization of innovative medicines and vaccines, today announced top-line results from a China Phase I study on healthy subjects demonstrating that...
Asieris Appoints Dr. Linda Wu as Chief Development Officer
SHANGHAI, Jan. 18, 2023 /PRNewswire/ -- Asieris Pharmaceuticals(688176.SH), a global biopharma company specializing in discovering, developing and commercializing innovative drugs for the treatment of genitourinary tumors and other related diseases, announced that Linda Wu, Ph.D. will join Asieris as Chief Development Officer today, effective January 17, 2023. She will be a member of Asieris' executive leadership team, play a key...
